首页> 外文期刊>International journal of hyperthermia: The official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group >Safety assessment and therapeutic efficacy of percutaneous microwave ablation therapy combined with percutaneous ethanol injection for hepatocellular carcinoma adjacent to the gallbladder
【24h】

Safety assessment and therapeutic efficacy of percutaneous microwave ablation therapy combined with percutaneous ethanol injection for hepatocellular carcinoma adjacent to the gallbladder

机译:经皮微波消融联合经皮乙醇注射液治疗胆囊旁肝细胞癌的安全性评估和疗效

获取原文
           

摘要

Objective: This study sought to evaluate the safety and efficacy of ultrasound-guided (US-guided) percutaneous microwave (MW) ablation combined with percutaneous ethanol injection (PEI) to treat liver tumours adjacent to the gallbladder. Materials and methods: A total of 136 patients with hepatocellular carcinoma (HCC) adjacent to the gallbladder, who underwent ultra-sonographically-guided percutaneous MW ablation, which was combined with PEI in132 patients, were retrospectively assessed. The patient population characteristics, tumour features, local tumour progression and treatment were compared and analysed. The safety and efficacy of the therapy were assessed by clinical data and imaging in follow-up examinations. Results: All patients were completely treated with two sessions; 120 patients underwent one session, 16 patients underwent two sessions. The primary technique was effective in 95.6% of the cases, according to the computed tomography (CT) or magnetic resonance imaging (MRI) in the one-month follow-up (132 of 138 sessions). PEI and other therapies were performed in the patients who had been incompletely treated (all six patients underwent PEI, and some underwent other therapies, including one transcatheter arterial chemoembolisation (TACE), one liver transplantation and two liver resections). There was a median follow-up period of 30.1 months and a range of 4 to 68 months. None of the patients had major complications. There were no treatment-related deaths. Twenty-six patients died of primary disease progression that was not directly attributable to MW ablation (19.1%, 26/136). Local tumour progression was noted in five patients (3.7%, 5/136), who had completely ablated tumours at follow-up. The patients with locally progressing tumours underwent additional therapy (three patients underwent PEI, one patient TACE, and one liver resection). Conclusion: Ultrasound-guided percutaneous MW ablation, in combination with percutaneous ethanol injection and thermal monitoring, is a safe and effective treatment for HCC adjacent to the gallbladder.
机译:目的:本研究旨在评估超声引导(US引导)经皮微波(MW)消融结合经皮乙醇注射(PEI)治疗胆囊附近肝肿瘤的安全性和有效性。材料和方法:回顾性评估了136例胆囊附近的肝细胞癌(HCC),他们接受了超声引导下的经皮MW消融术,并与PEI相结合,对132例患者进行了回顾性评估。比较并分析了患者的人群特征,肿瘤特征,局部肿瘤进展和治疗情况。在后续检查中通过临床数据和影像学评估了该疗法的安全性和有效性。结果:所有患者均接受了两次疗程的完全治疗; 120例患者进行了一次治疗,16例患者进行了两次治疗。根据计算机断层扫描(CT)或磁共振成像(MRI)的一项为期1个月的随访(138例中的132例),主要技术在95.6%的病例中有效。对未完全治疗的患者进行了PEI和其他疗法(所有6例患者均接受了PEI,一些患者接受了其他疗法,包括1例经导管动脉化疗栓塞(TACE),1例肝移植和2例肝切除术)。中位随访期为30.1个月,范围为4到68个月。所有患者均无重大并发症。没有与治疗有关的死亡。 26例患者死于原发性疾病进展,而该进展并非直接归因于MW消融(19.1%,26/136)。在随访中发现5例患者的局部肿瘤进展(3.7%,5/136)已完全消融。患有局部进展性肿瘤的患者接受了额外的治疗(3例接受PEI,1例TACE和1例肝切除术)。结论:超声引导下经皮微波消融结合经皮乙醇注射和热监测,是一种安全有效的治疗胆囊癌的方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号